“Chris joined us at a crucial time in Cyteir’s development. He and TechCXO helped to transform the company’s financial operations from start-up to public company, which prepared us well for our recent IPO (June 2021). In addition, Chris became a trusted partner and integral member of the leadership team, providing thoughtful advice based on years of experience in building biotech companies. Chris interacted with our Board of Directors and investors on a regular basis and played a key role with our fundraising strategy up to and including the IPO.”
Markus Renschler, MD, President and Chief Executive Officer
Cyteir Therapeutics, Inc.